Stem Cell Therapy for Alzheimer's Looks Safe, but Proof of Benefit Is Still Missing
A review of 17 trials finds mesenchymal stem cells are feasible and generally safe in Alzheimer's, but efficacy is unproven and only some results hint at benefit.
Riepilogo
Alzheimer's disease has no treatment that stops neurodegeneration, and current drugs only ease symptoms. This review examined clinical trials of mesenchymal stem cells (MSCs) registered or published between 2011 and June 2025. Seventeen trials and four related papers were analyzed. Most trials were early-stage (phase 1 or 1/2), used cells from umbilical cord blood, adipose tissue, umbilical cord, bone marrow or placenta, and gave them mostly by IV infusion. Results had been reported for only seven trials. All five reports described MSC administration as safe. Two reports on bone marrow-derived Lomecel-B showed meaningful improvements in Alzheimer's pathophysiology or cognition. Reports on NEUROSTEM-AD and AstroStem showed no statistically significant efficacy. The authors conclude that MSC therapy is feasible and generally safe, but benefit is unproven because of small samples and variable cell sources, doses and delivery schedules.
Riepilogo Dettagliato
Alzheimer's disease (AD) remains a major unmet medical need. Available drugs relieve symptoms but do not stop the underlying neurodegeneration. Mesenchymal stem cells (MSCs) are being widely studied as a possible disease-modifying approach, but their clinical value has not been verified. This review aimed to assess what human trials show so far.
The authors searched ClinicalTrials.gov, PubMed, Web of Science and SCOPUS for publications and registered trials from January 2011 to June 2025. They used the keywords "Alzheimer's disease," "mesenchymal stem cells" and "clinical trials." After screening, 17 clinical trials and 4 related papers were analyzed in depth.
The trials were mostly early-phase: 4 phase 1, 9 phase 1/2, 3 phase 2 and 1 pilot. MSC sources were allogeneic umbilical cord blood (5 trials), autologous adipose tissue (4), allogeneic umbilical cord (3), allogeneic bone marrow (3), allogeneic placenta (1) and one unknown. Delivery was mainly intravenous (12 trials). Three trials used intracerebroventricular infusion via an Ommaya reservoir, and two used stereotactic brain injection. Outcome data were available for only 7 trials, across 4 papers and 1 ClinicalTrials.gov results posting. These covered NEUROSTEM-AD (umbilical cord blood MSCs, 4 trials in 2 papers), Lomecel-B (bone marrow MSCs, 2 trials in 2 papers) and AstroStem (adipose MSCs, 1 trial).
All five reports, which differed in cell type, route and dose, described MSC administration as safe. On efficacy the picture was mixed. The two Lomecel-B reports described meaningful improvement in AD pathophysiology or cognitive function. The three reports on NEUROSTEM-AD or AstroStem did not show statistically significant efficacy.
The authors conclude that MSC therapy is feasible and generally safe in AD patients, with signs of possible benefit on cognition or quality of life in some patients. They state that efficacy is not definitively proven. Small subject numbers and heterogeneity in dose, MSC source, route, timing and frequency limit conclusions. Larger, well-controlled trials are needed. Note that this summary draws on the abstract and metadata, because the full text was not available, so trial-level details such as sample sizes, doses and effect sizes are not covered.
Risultati Principali
- Seventeen MSC trials in Alzheimer's were identified, mostly early-phase: 4 phase 1, 9 phase 1/2, 3 phase 2 and 1 pilot.
- Cell sources varied: umbilical cord blood (5 trials), adipose (4), umbilical cord (3), bone marrow (3) and placenta (1).
- Intravenous infusion was the dominant route (12 of 17 trials); Ommaya reservoir and stereotactic brain injection were used in 5.
- All five outcome reports, from 7 trials, described MSC administration as safe across cell types, routes and doses.
- Lomecel-B reports showed meaningful pathophysiology or cognitive improvements; NEUROSTEM-AD and AstroStem showed no significant efficacy.
Metodologia
Literature review of clinical trials registered or published from January 2011 to June 2025, searching ClinicalTrials.gov, PubMed, Web of Science and SCOPUS. After screening, 17 trials and 4 related papers were analyzed. This summary is based on the abstract only, as the full text was not available.
Limitazioni dello Studio
Most trials were early-phase with small samples. Cell source, dose, route, timing and frequency varied widely, and outcome data existed for only 7 of 17 trials, with mixed efficacy. Because only the abstract was available, details on trial design, controls, effect sizes and adverse events could not be assessed, and the conclusions are those the authors report.
Ti è piaciuto questo riepilogo?
Ricevi ogni settimana le ultime ricerche sulla longevità direttamente nella tua casella email.
Inserisci la tua email per iscriverti: